102 related articles for article (PubMed ID: 23893665)
1. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?
Josselin-Mahr L; Werbrouck-Chiraux A; Garderet L; Cabane J
Rheumatology (Oxford); 2014 Feb; 53(2):378-9. PubMed ID: 23893665
[No Abstract] [Full Text] [Related]
2. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?
Erre GL; Pardini S; Cuccuru L; Taras L; Passiu G
Joint Bone Spine; 2015 Jan; 82(1):72-3. PubMed ID: 25059880
[No Abstract] [Full Text] [Related]
3. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
Levitzki A
Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
[TBL] [Abstract][Full Text] [Related]
4. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
Parikh PM; Gupta S
Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans].
Moiseenko VM; Chudenko VA; Orlova RV; Imianitov EN; Matsko DE; Gafton GI; Kochnev VA; Protsenko SA; Mikhaĭlichenko TD; Nogaeva TKh
Vopr Onkol; 2008; 54(5):656-60. PubMed ID: 19069485
[No Abstract] [Full Text] [Related]
6. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
Imataki O
Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
[No Abstract] [Full Text] [Related]
7. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.
Eklund KK; Lindstedt K; Sandler C; Kovanen PT; Laasonen L; Juurikivi A; Wolff H; Mykkänen M; Joensuu H
J Clin Rheumatol; 2008 Oct; 14(5):294-6. PubMed ID: 18824923
[No Abstract] [Full Text] [Related]
8. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
[No Abstract] [Full Text] [Related]
9. [Updates on pathology of soft tissue tumors].
Yu L; Wang J
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):145-6. PubMed ID: 23769430
[No Abstract] [Full Text] [Related]
10. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib.
Bournia VK; Evangelou K; Sfikakis PP
Semin Arthritis Rheum; 2013 Feb; 42(4):377-90. PubMed ID: 22789835
[TBL] [Abstract][Full Text] [Related]
11. Reversal of vascular leak with imatinib.
Aman J; Peters MJ; Weenink C; van Nieuw Amerongen GP; Vonk Noordegraaf A
Am J Respir Crit Care Med; 2013 Nov; 188(9):1171-3. PubMed ID: 24180451
[No Abstract] [Full Text] [Related]
12. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Agarwal MB
J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
[No Abstract] [Full Text] [Related]
13. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
14. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
15. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor.
Ascione L; De Michele M; Accadia M; Spadaro P; Rumolo S; Tuccillo B
Eur J Echocardiogr; 2004 Oct; 5(5):386-90. PubMed ID: 15341874
[TBL] [Abstract][Full Text] [Related]
16. The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor.
Wang JP; Wang T; Huang MJ; Wang L; Kang L; Wu XJ
Am J Clin Oncol; 2011 Jun; 34(3):314-6. PubMed ID: 20622646
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for imatinib in inflammatory bowel disease?
De Backer O; Lefebvre RA
Inflamm Bowel Dis; 2008 Apr; 14(4):579-81. PubMed ID: 18050299
[No Abstract] [Full Text] [Related]
18. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.
Stadler M; Ahlborn R; Kamal H; Diedrich H; Buchholz S; Eder M; Ganser A
Blood; 2009 Oct; 114(17):3718-9; author reply 3719-20. PubMed ID: 19850751
[No Abstract] [Full Text] [Related]
19. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
Antoniu SA
Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
[TBL] [Abstract][Full Text] [Related]
20. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
